Oncolytics Biotech Inc T.ONC

Roche anti-TIGIT hope turns to Tecentriq

[Noteable]

Roche's anti-TIGIT drug tiragolumab also has not done very well - placing Roche's continued hope on their immune checkpoint inhibitor Tecentriq.

https://www.reuters.com/business/healthcare-pharmaceuticals/roches-late-stage-trial-two-lung-cancer-drugs-fails-2022-05-11/

[Angler101]

Notable...Thank you once again for your (and other’s) constant barrage of much appreciated incredibly pertinent information supporting the argument for our little virus finally getting bought out and eventually approved for helping out many thousands and perhaps many millions of cancer victims in what seemingly could be scores of indications. You and other posters here are obviously very

[Buckhenry]

Yes I would like to thank all the dreamers for their constant barage of worthless posts about all the other companies that have been bought for jillions of dollars.... and how does this relate to oncy... is their a direct correlation here. Or is it all hot air and wishful thinking... well... perhaps or maybe I suppose. 

[Noteable]

Here is another :  " In March 2023, Merck & Co.'s TIGIT therapy tacked on to Keytruda did not improve progression-free survival in a phase 2 lung cancer trial, marking the another failure for the class." Then in June 2023 Novartis ended its partnership with BeiGene on their TIGIT target. https://www.fiercebiotech.com/biotech/merck-tacks-another-loss-anti-tigits

[Noteable]

All this is effectively related to ONCY given pelareorep's ability to convert an otherwise immunosuppressive tumor microenvironment (TME) into one that is favorable to combination immunotherapy, and do so synergistically.

[Noteable]

So ... for those who got lost on the way here, this again bring up the subject of triplet therapy involving ONCY's pelareorep. Therfore, how we got here is not in the same way to where we are going.

[Noteable]

January 09, 2024 - Coherus BioSciences axes TIGIT.  Coherus’ decision to cut its losses follows a series of events that have caused confidence in TIGIT, a target that was once a hot property, to ebb and flow. Roche has ridden out setbacks to emerge with evidence that its candidate may improve overall survival in first-line non-small cell lung cancer. Gilead and Merck & Co. have